2016
DOI: 10.1055/s-0036-1585551
|View full text |Cite
|
Sign up to set email alerts
|

Urolithiasis bei der Langzeitherapie mit GnRH-Agonisten bei Paraphilien – 3 Fallberichte

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…As shown by current research, a loss of bone mineral density can be found especially during LHRH agonist treatment. 43,70 Thus, bone mineral density should be measured at baseline and at least every 2 years. As suggested by a recent case report, osteopenia or osteoporosis after LHRH agonist treatment also might cause the development of calcium-oxalate urinary stones that could ultimately lead to acute or chronic kidney failure.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…As shown by current research, a loss of bone mineral density can be found especially during LHRH agonist treatment. 43,70 Thus, bone mineral density should be measured at baseline and at least every 2 years. As suggested by a recent case report, osteopenia or osteoporosis after LHRH agonist treatment also might cause the development of calcium-oxalate urinary stones that could ultimately lead to acute or chronic kidney failure.…”
Section: Discussionmentioning
confidence: 99%
“…As suggested by a recent case report, osteopenia or osteoporosis after LHRH agonist treatment also might cause the development of calcium-oxalate urinary stones that could ultimately lead to acute or chronic kidney failure. 70 Furthermore, in patients who do not show a decrease in serum testosterone and serum LH and follicle-stimulating hormone levels after the first 4 weeks of LHRH agonist treatment, conducting a brain MR scan should be considered to identify structural abnormalities, especially anomalies of the pituitary gland, because of the risk of pituitary apoplexy under LHRH agonist treatment. 68 Importantly, pituitary apoplexy can occur in hormone-active and hormone-inactive adenomas, indicating that measurements of serum hormone concentrations might not be sufficient to detect patients at risk (the patient described in the present review had normal thyroid-stimulating hormone, thyroxine, prolactin, LH, follicle-stimulating hormone, testosterone, corticotrophin, and cortisol serum concentrations before LHRH agonist treatment was initiated).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations